You are here
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials
RUTHERFORD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation and commercial launch of Thermo Fisher Scientific’s next-generation sequencing (NGS) Oncomine™ Comprehensive Assay v3 for biopharma clinical trials.
John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “As we have previously announced, we are continuing to gain momentum with key channel partners. Oncomine™ Comprehensive Assay v3 provides confidence in understanding cancer mutations. This newest version of the assay supports both translational and clinical researchers with superior tumor profiling capabilities that enable reliable results. We are excited about the potential of the Oncomine Comprehensive Assay in drastically improving clinical oncology research.”
Oncomine Comprehensive Assay v3 features content based on the advances in clinical oncology research. It enables simultaneous analysis of DNA and RNA to detect hundreds of variant types, including single nucleotide variants (SNVs), copy number variations (CNVs), gene fusions, and indels from unique cancer driver genes, across 161 genes relevant to solid tumors.
It also covers the entire kinase domain in several critical receptor tyrosine kinases, which increases the likelihood of detecting functionally relevant mutations in addition to known actionable and prevalent variants. Additionally, the assay represents 31 genes involved in the DNA repair pathway and covers MAPK, PI3K, and cell cycle pathway genes.
Oncomine™ Comprehensive Assay v3 requires only 10 ng of DNA or RNA per pool to deliver analysis of even small and challenging formalin-fixed, paraffin-embedded (FFPE) samples. It is optimized for automated library preparation using the Ion Chef System and rapid sequencing on the Ion GeneStudio S5 Systems with analysis reporting using the Oncomine™ Knowledgebase Reporter, which aligns results with the most recent published evidence on clinical oncology research.
For more information, please visit or follow CGI at:
Forward Looking Statements:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. tests and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or bookings or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, uncertainties with respect to evaluating strategic options, maintenance of intellectual property rights, uncertainty of collections from Medicare and third party payors for novel tests and services and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
The Ruth Group